SMOFKABIVEN DIN 02440695
Health Canada record
| Active ingredient(s) | SOYBEAN OIL 1.14 G; MEDIUM CHAIN TRIGLYCERIDES (MCT) 1.14 G; OLIVE OIL 0.95 G; FISH OIL 0.57 G; DEXTROSE 12.7 G; LYSINE (LYSINE ACETATE) 0.34 G; PHENYLALANINE 0.26 G; LEUCINE 0.38 G; VALINE 0.31 G; THREONINE 0.22 G; METHIONINE 0.22 G; ISOLEUCINE 0.25 G; TRYPTOPHAN 0.1 G; ALANINE 0.71 G; ARGININE 0.61 G; GLYCINE 0.56 G; PROLINE 0.57 G; HISTIDINE 0.15 G; SERINE 0.33 G; TAURINE 0.05 G; TYROSINE 0.02 G; SODIUM ACETATE TRIHYDRATE 0.17 G; POTASSIUM CHLORIDE 0.23 G; SODIUM GLYCEROPHOSPHATE 0.21 G; MAGNESIUM SULFATE 0.061 G; CALCIUM CHLORIDE 0.028 G; ZINC SULFATE HEPTAHYDRATE 0.00066 G |
|---|---|
| Dosage form | Emulsion |
| Route | Intravenous |
| Schedule | ETHICAL |
| Class | Human |
| ATC | B05BA10 COMBINATIONS |
| Original market date | 15-Sep-2015 |
| Current status date | 15-Sep-2015 |
| Source | Health Canada DPD |
Establishment licence of the holder
Fresenius Kabi Canada Ltd. — licence 102232, currently licensed, last inspection rating C (2025-10-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SOYBEAN OIL
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02065673 | INTRALIPID 20% | FRESENIUS KABI CANADA LTD | Emulsion | SOYBEAN OIL 20 % | Marketed |
| 02440687 | SMOFKABIVEN ELECTROLYTE FREE | FRESENIUS KABI CANADA LTD | Emulsion | SOYBEAN OIL 1.14 G; MEDIUM CHAIN TRIGLYCERIDES (MCT) 1.14 G; OLIVE OIL 0.95 G; FISH OIL 0.57 G; DEXTROSE 12.7 G; LYSINE (LYSINE ACETATE) 0.34 G; PHENYLALANINE 0.26 G; LEUCINE 0.38 G; VALINE 0.31 G; THREONINE 0.22 G; METHIONINE 0.22 G; ISOLEUCINE 0.25 G; TRYPTOPHAN 0.1 G; ALANINE 0.71 G; ARGININE 0.61 G; GLYCINE 0.56 G; PROLINE 0.57 G; HISTIDINE 0.15 G; SERINE 0.33 G; TAURINE 0.05 G; TYROSINE 0.02 G | Marketed |
| 02396963 | SMOFLIPID 20% | FRESENIUS KABI CANADA LTD | Emulsion | SOYBEAN OIL 6 %; MEDIUM CHAIN TRIGLYCERIDES (MCT) 6 %; OLIVE OIL 5 %; FISH OIL 3 % | Marketed |
| 02016028 | 10% TRAVAMULSION LIQ IV | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | Liquid | SOYBEAN OIL 10 G; EGG PHOSPHOLIPIDS 1.2 G | Cancelled Post Market |
| 02016036 | 20% TRAVAMULSION LIQ IV | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | Liquid | SOYBEAN OIL 20 G; EGG PHOSPHOLIPIDS 1.2 G | Cancelled Post Market |
| 02065681 | INTRALIPID 10% | FRESENIUS KABI CANADA LTD | Emulsion | SOYBEAN OIL 10 % | Dormant |
| 02216175 | INTRALIPID 30% | FRESENIUS KABI CANADA LTD | Emulsion | SOYBEAN OIL 30 % | Dormant |
| 02366800 | LIPOSYN III 10% | HOSPIRA HEALTHCARE ULC | Emulsion | SOYBEAN OIL 100 MG; EGG PHOSPHOLIPIDS 12 MG | Cancelled Post Market |
| 02366819 | LIPOSYN III 20% | HOSPIRA HEALTHCARE ULC | Emulsion | SOYBEAN OIL 200 MG; EGG PHOSPHOLIPIDS 12 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 16874 | 2015-05-06 | New Drug Submission (NDS) |
International API supply for SOYBEAN OIL
5 active FDA Drug Master Files.
Request a quote for SMOFKABIVEN